Author: Vere Hodge, R Anthony
Title: Meeting report: 30th International Conference on Antiviral Research, in Atlanta, GA, USA Document date: 2018_6_28
ID: tudwns0r_24
Snippet: In a Phase II/III trial clevudine was dosed (30 mg once daily) for 24 weeks. In HBeAg(þ) (hepatitis B antigen positive) patients, HBV DNA levels continued to decrease during the dosing period to 5.1 log 10 copies/ml below baseline. During the 24 weeks after dosing, HBV DNA levels rose slowly but were still 2 log 10 copies/ml below baseline. In HBeAg(À) patients, the decrease in HVB DNA levels was similar (4.25 log 10 copies/ml) but then rose ve.....
Document: In a Phase II/III trial clevudine was dosed (30 mg once daily) for 24 weeks. In HBeAg(þ) (hepatitis B antigen positive) patients, HBV DNA levels continued to decrease during the dosing period to 5.1 log 10 copies/ml below baseline. During the 24 weeks after dosing, HBV DNA levels rose slowly but were still 2 log 10 copies/ml below baseline. In HBeAg(À) patients, the decrease in HVB DNA levels was similar (4.25 log 10 copies/ml) but then rose very slowly to 3.1 log 10 copies/ml below baseline at 24 weeks after dosing. Presently, clevudine is marketed by EISAI (Japan) in South Korea, Thailand and the Philippines. NDAs (new drug applications) have been filed in various other Asian countries. In the USA, Phase III trials were discontinued by Pharmasset.
Search related documents:
Co phrase search for related documents- dose period and phase iii trial: 1, 2
- drug application and new drug application: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- drug application and phase iii trial: 1
Co phrase search for related documents, hyperlinks ordered by date